Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer

Abstract Background The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain uncertain, along with the specific patient subgroups that may gain the most from this approach. This retrospective study aim...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jing Cheng, Wenwen Kang, Yueying Chen, Luyun Pan, Hedong Han, Tangfeng Lv
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2025-02-01
coleção:	Cancer Immunology, Immunotherapy
Assuntos:	Non-small cell lung cancer (NSCLC) Small cell lung cancer (SCLC) Immune checkpoint inhibitors (ICIs) Immunotherapy beyond progression (IBP) Efficacy
Acesso em linha:	https://doi.org/10.1007/s00262-025-03958-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!